



TO MAGNIFICO RETTORE OF UNIVERSITA' DEGLI STUDI DI MILANO

I the undersigned asks to participate in the public selection, for qualifications and examinations, for the awarding of a type A post-doc fellowship

[Prasanth Saraswati Akella]

CURRICULUM VITAE

PERSONAL INFORMATION

Surname	Akella
Name	Prasanth Saraswati
Date of birth	[25, October, 2020]

PRESENT OCCUPATION

Appointment	Structure
Associate Sceintific Writer	Indegene Pvt Ltd

EDUCATION AND TRAINING

Degree	Course of studies	University	year of achievement of the degree
Degree	Bachelors of Pharmacy	Rajiv Gandhi University of Health Sciences	2013
Specialization			
PhD	Medicinal Chemistry	Universita degli Studi di Siena	2020
Master	Medicinal Chemistry	NIPER, Hyderabad	2016
Degree of medical specialization			
Degree of European specialization			
Other			



REGISTRATION IN PROFESSIONAL ASSOCIATIONS

Date registration	of	Association	City

FOREIGN LANGUAGES

Languages	level of knowledge
English	Expert

AWARDS, ACKNOWLEDGEMENTS, SCHOLARSHIPS

Year	Description of award
2017	Marie Curie Fellowship supported by the Marie Skłodowska-Curie Actions
2014	NIPER Fellowship

TRAINING OR RESEARCH ACTIVITY

description of activity

PROJECT ACTIVITY

Year	Project
2017-2020	Development of new drugs for the treatment of oral cancers.
2015-2016	Design, synthesis, and biological evaluation of novel HDAC inhibitors as anticancer agents.

PATENTS

Patent

CONGRESSES AND SEMINARS

Date	Title	Place
July 2019	ESMEC	URBINO, ITALY
July 2018	ESMEC	URBINO, ITALY
July 2017	ESMEC	URBINO, ITALY



PUBLICATIONS

Books
Recent Advances on Inhibitors of Apoptosis Proteins (IAP) Particularly with Reference to Patents, India, Wiley, 2017

Articles in reviews
(+)-(R)-and (-)-(S)-Perhexiline maleate: Enantioselective synthesis and functional studies on Schistosoma mansoni larval and adult stages, Bioorganic Chemistry, Siena, Elsevier, 2020
Telomerase-based cancer therapeutics: a review on their clinical trials, Current topics in Medicinal Chemistry, Siena, Bentham, 2020
Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents, ACS Infectious Diseases, Siena, American Chemical Society, 2019
Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases, Journal of Medicinal Chemistry, Siena, American Chemical Society, 2019
Raising the bar in anticancer therapy: Recent advances in, and perspectives on, telomerase inhibitors, Drug Discovery Today, Siena, Elsevier, 2019
Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions, European Journal of Medicinal Chemistry, India, Elsevier, 2018
Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance, Current Medicinal Chemistry, India, Bentham, 2017
Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents, MedChemComm, India, Royal Society of Chemistry, 2017
Silver catalyzed domino aza-annulation/Diels-Alder cyclization of 2-ene-yne anilines: a facile one-pot access to carbazole, dihydrocarbazole and tetrahydrocarbazole frameworks, Chemical Communications, India, Royal Society of Chemistry, 2016

Congress proceedings
Development of new drugs for the treatment of oral cancers, Poster, Urbino, 2019
Development of novel HDAC6 inhibitors for the treatment of cancer and rare diseases, Oral, Siena, 2019
Mcl-1 inhibitors in the treatment of oral squamous cell carcinoma, Poster, Urbino, 2018

OTHER INFORMATION

Declarations given in the present curriculum must be considered released according to art. 46 and 47 of DPR n. 445/2000.

The present curriculum does not contain confidential and legal information according to art. 4, paragraph



UNIVERSITÀ DEGLI STUDI DI MILANO

1, points d) and e) of D.Lgs. 30.06.2003 n. 196.

Place and date: Hyderabad, 26-09-2020

SIGNATURE

Akella Prasanth Saraswati